Press Releases

Date	Title
Feb 29, 2024	Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update – ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and Equivalents at December 31, 2023 – – Conference Call at 8:30 a.m.
Feb 27, 2024	Chimerix to Present at TD Cowen 44th Annual Health Care Conference DURHAM, N.C. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole , Chief Executive Officer, will
Feb 22, 2024	Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 DURHAM, N.C. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on